Royal Bank of Canada’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13M | Sell |
397,968
-57,450
| -13% | -$1.85M | ﹤0.01% | 1742 |
|
|
2025
Q4 | $16M | Sell |
455,418
-192,877
| -30% | -$6.83M | ﹤0.01% | 1637 |
|
|
2025
Q3 | $17M | Buy |
648,295
+36,598
| +6% | +$1.09M | ﹤0.01% | 1773 |
|
|
2025
Q2 | $16.2M | Buy |
611,697
+263,981
| +76% | +$6.95M | ﹤0.01% | 1688 |
|
|
2025
Q1 | $8.4M | Buy |
347,716
+39,886
| +13% | +$1.26M | ﹤0.01% | 1876 |
|
|
2024
Q4 | $12.4M | Sell |
307,830
-88,063
| -22% | -$5.02M | ﹤0.01% | 1668 |
|
|
2024
Q3 | $25.1M | Buy |
395,893
+129,010
| +48% | +$7.57M | 0.01% | 1212 |
|
|
2024
Q2 | $14.1M | Buy |
266,883
+140,491
| +111% | +$9.21M | ﹤0.01% | 1454 |
|
|
2024
Q1 | $10.4M | Buy |
126,392
+55,626
| +79% | +$2.48M | ﹤0.01% | 1663 |
|
|
2023
Q4 | $1.32M | Buy |
70,766
+58,105
| +459% | +$760K | ﹤0.01% | 3438 |
|
|
2023
Q3 | $140K | Sell |
12,661
-2,319
| -15% | -$33.2K | ﹤0.01% | 5119 |
|
|
2023
Q2 | $243K | Buy |
14,980
+13,978
| +1,395% | +$293K | ﹤0.01% | 4565 |
|
|
2023
Q1 | $17K | Buy |
1,002
+402
| +67% | +$4.15K | ﹤0.01% | 6094 |
|
|
2022
Q4 | $6K | Buy |
600
+284
| +90% | +$1.27K | ﹤0.01% | 6701 |
|
|
2022
Q3 | $1K | Buy |
316
+216
| +216% | +$707 | ﹤0.01% | 7290 |
|
|
2022
Q2 | $0 | Sell |
100
-4,103
| -98% | -$10.2K | ﹤0.01% | 7743 |
|
|
2022
Q1 | $13K | Sell |
4,203
-16,566
| -80% | -$59.4K | ﹤0.01% | 6847 |
|
|
2021
Q4 | $95K | Sell |
20,769
-36,399
| -64% | -$204K | ﹤0.01% | 5986 |
|
|
2021
Q3 | $359K | Buy |
57,168
+5,834
| +11% | +$36K | ﹤0.01% | 4626 |
|
|
2021
Q2 | $307K | Buy |
51,334
+2,392
| +5% | +$14.2K | ﹤0.01% | 4704 |
|
|
2021
Q1 | $309K | Buy |
48,942
+12,118
| +33% | +$85.3K | ﹤0.01% | 4588 |
|
|
2020
Q4 | $207K | Sell |
36,824
-9,604
| -21% | -$58.2K | ﹤0.01% | 4834 |
|
|
2020
Q3 | $271K | Sell |
46,428
-2,008
| -4% | -$13.8K | ﹤0.01% | 4327 |
|
|
2020
Q2 | $349K | Buy |
48,436
+781
| +2% | +$5.19K | ﹤0.01% | 4055 |
|
|
2020
Q1 | $223K | Buy |
47,655
+1,693
| +4% | +$10.4K | ﹤0.01% | 4254 |
|
|
2019
Q4 | $368K | Sell |
45,962
-2,067
| -4% | -$15.1K | ﹤0.01% | 4200 |
|
|
2019
Q3 | $331K | Buy |
48,029
+667
| +1% | +$4.95K | ﹤0.01% | 4112 |
|
|
2019
Q2 | $393K | Sell |
47,362
-1,202
| -2% | -$10.3K | ﹤0.01% | 4009 |
|
|
2019
Q1 | $483K | Buy |
48,564
+12,994
| +37% | +$109K | ﹤0.01% | 3745 |
|
|
2018
Q4 | $272K | Buy |
35,570
+30,259
| +570% | +$362K | ﹤0.01% | 4141 |
|
|
2018
Q3 | $93K | Buy |
5,311
+2,191
| +70% | +$26.1K | ﹤0.01% | 4900 |
|
|
2018
Q2 | $29K | Sell |
3,120
-481
| -13% | -$3.2K | ﹤0.01% | 5393 |
|
|
2018
Q1 | $16K | Buy |
3,601
+600
| +20% | +$3.32K | ﹤0.01% | 5541 |
|
|
2017
Q4 | $12K | Buy |
3,001
+3,000
| +300,000% | +$8.71K | ﹤0.01% | 5804 |
|
|
2017
Q3 | $0 | Buy |
+1
| New | +$1 | ﹤0.01% | 7009 |
|
|
2016
Q1 | – | Sell |
-3,125
| Closed | -$18K | – | 6668 |
|
|
2015
Q4 | $18K | Buy |
+3,125
| New | +$14K | ﹤0.01% | 5758 |
|
Other funds holding VKTX
VCM
VPM
Royal Bank of Canada's VKTX Position: Q1 2026 in Review
Royal Bank of Canada reduced its Viking Therapeutics (VKTX) stake by 13% in Q1 2026, selling an estimated $1.85M and leaving 397,968 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #1742.
Royal Bank of Canada first reported a position in VKTX in Q4 2015 and has held it in 36 quarters since. The position peaked at $25.1M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Royal Bank of Canada held 397,968 shares of Viking Therapeutics worth $13M as of Q1 2026.
- Royal Bank of Canada sold 57,450 Viking Therapeutics shares in Q1 2026, an estimated $1.85M.
- Viking Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1742 holding.
- Royal Bank of Canada first reported a position in Viking Therapeutics in Q4 2015 and has held it in 36 quarters since.
- Royal Bank of Canada's Viking Therapeutics position peaked at $25.1M in Q3 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.